Eli Lilly and Company (NYSE:LLY) Shares Sold by Legend Financial Advisors Inc.

Legend Financial Advisors Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 350 shares of the company’s stock after selling 19 shares during the quarter. Legend Financial Advisors Inc.’s holdings in Eli Lilly and Company were worth $204,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Fairfield Bush & CO. acquired a new position in Eli Lilly and Company in the first quarter valued at $107,000. Roundview Capital LLC lifted its stake in shares of Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after purchasing an additional 53 shares in the last quarter. Merit Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the first quarter worth about $210,000. NewEdge Advisors LLC lifted its stake in shares of Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after purchasing an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in shares of Eli Lilly and Company during the first quarter worth about $561,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.6 %

Shares of Eli Lilly and Company stock opened at $726.31 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market cap of $690.11 billion, a P/E ratio of 125.23, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $369.76 and a fifty-two week high of $800.78. The business has a 50-day moving average price of $763.96 and a 200 day moving average price of $660.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the company earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, sell-side analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have commented on the company. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Bank of America boosted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.